CoverageForm 410-K10-Q8-K13D13G13F

ELUT · Elutia Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · ELUT

Income Statement

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue------
Cost of Revenue$5.70M$13.67M$13.69M$29.96M$28.37M$22.12M
Gross Profit$6.60M$10.71M$11.05M$19.22M$19.02M$20.56M
R&D$4.16M$3.79M$4.40M$8.94M$9.27M$4.08M
SG&A$15.08M$18.66M$14.10M$16.63M$13.96M$13.23M
Total Operating Expenses$33.51M$46.36M$41.58M$50.96M$42.05M$34.16M
D&A$2.79M$3.45M$3.75M$3.73M$3.73M$3.86M
Operating Income($26.91M)($35.65M)($30.53M)($31.74M)($23.03M)($13.60M)
Interest Expense-$4.78M$5.80M$5.28M$5.32M$5.63M
Income Tax$13.0K$7.0K$28.0K$34.0K$55.0K$26.0K
Net Income$53.38M($53.95M)($37.66M)($32.90M)($24.83M)($21.82M)
EPS - Basic$1.29($1.86)($2.07)($2.38)($8.88)-
EPS - Diluted$0.87($1.86)($2.07)($2.38)($8.88)-

Balance Sheet

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash & Equivalents$36.35M$13.24M$19.28M$16.99M$30.39M$39.15M
Accounts Receivable$1.73M$2.28M$3.26M$6.83M$6.00M$7.17M
Inventory$2.62M$3.91M$3.85M$10.05M$9.55M$10.12M
Accounts Payable$4.79M$4.15M$2.29M$2.33M$1.58M$2.05M
Current Assets$55.82M$26.17M$31.25M$50.70M$47.43M$59.71M
Total Assets$62.35M$36.13M$43.43M$68.84M$67.17M$82.81M
Current Liabilities$25.14M$37.80M$43.04M$42.62M$26.00M$26.78M
Long-term Debt$21.10M$22.60M$20.36M$24.26M$10.41M$17.81M
Total Liabilities$34.68M$82.39M$82.03M$73.87M$53.65M$61.98M
Stockholders' Equity$27.67M($46.26M)($38.60M)($5.03M)$13.52M$20.83M
Retained Earnings($176.21M)($229.59M)($175.64M)($137.99M)($105.09M)($80.26M)

Cash Flow

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Cash Flow($44.81M)($22.66M)($21.76M)($21.43M)($15.45M)($13.63M)
Investing Cash Flow$78.56M($474.0K)$14.21M($540.0K)($369.0K)($640.0K)
Financing Cash Flow($10.64M)$17.09M$9.84M$8.54M$6.71M$51.21M
CapEx$1.88M$654.0K$346.0K$540.0K$369.0K$640.0K
Free Cash Flow($46.69M)($23.31M)($22.11M)($21.97M)($15.81M)($14.27M)

Ratios

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Profitability
Gross margin------
Operating margin------
EBITDA margin------
Net margin------
Free cash flow margin------
FCF / Net income-0.870.430.590.670.640.65
R&D / Revenue------
SG&A / Revenue------
Effective tax rate0.0%-----
Return on assets85.6%-149.3%-86.7%-47.8%-37.0%-26.4%
Return on equity192.9%116.6%97.6%653.6%-183.7%-104.8%
Return on invested capital-55.2%---130.4%-76.0%-27.8%
Liquidity
Current ratio2.220.690.731.191.822.23
Quick ratio2.120.590.640.951.461.85
Cash ratio1.450.350.450.401.171.46
Leverage
Debt / Equity0.76-0.49-0.53-4.820.770.86
Debt / Assets0.340.630.470.350.150.22
Debt / EBITDA------
Interest coverage--7.5x-5.3x-6.0x-4.3x-2.4x
Equity multiplier2.25-0.78-1.13-13.684.973.98
Liabilities / Assets0.562.281.891.070.800.75
Efficiency
Asset turnover------
Inventory turnover2.183.493.552.982.972.19
Days sales outstanding------
Days inventory outstanding168d104d103d122d123d167d
Days payable outstanding307d111d61d28d20d34d
Cash conversion cycle------
Valuation
P / E0.8x-----
P / B1.2x-----
P / S------
EV / EBITDA------
Growth
Revenue growth (YoY)------
Revenue CAGR (3y)------
Revenue CAGR (5y)------
Gross profit growth (YoY)-38.4%-3.1%-42.5%1.1%-7.5%-
Operating income growth (YoY)24.5%-16.8%3.8%-37.8%-69.4%-
Net income growth (YoY)--43.3%-14.5%-32.5%-13.8%-
EPS growth (YoY)-10.1%13.0%73.2%--
EPS CAGR (3y)------
EPS CAGR (5y)------
FCF growth (YoY)-100.3%-5.4%-0.6%-38.9%-10.9%-
FCF CAGR (5y)------
Book value growth (YoY)--19.8%-666.9%--35.1%-

Stability scores

Piotroski F-score

FY 2025 · 9-point quality

4/9
Neutral
  • Net income positive
  • Operating cash flow positive
  • ROA improved YoY
  • Cash flow > net income
  • Long-term debt decreased
  • Current ratio improved
  • No share dilution
  • -Gross margin improved
  • -Asset turnover improved

Peer comparison

Same SIC group: Biological Products, (No Diagnostic Substances)

CompanyRevenue (last FY)Net marginROE
TWST---16.4%
AMGN$36.75B21.0%89.1%
RXRX$74.68M-863.4%-57.0%
MRNA$1.94B-145.2%-32.6%
DNA$170.16M-183.8%-61.5%

Comparing ELUTIA INC. against the 5 most active filers in the same SIC group.

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.